Biotech
LONDON, ONTARIO: Focus on the clinical development of lead compound, COTI-2, continues
...
COLUMBIA, MD and TORONTO, ON: Poster Presentation Outlining the Pivotal Phase III Clinical Study Currently Being Investigated at VM Medical, the Largest Non Public Private Breast Center in Canada
...
WINSTON-SALEM, NC and PHILADELPHIA, PA: Dell Recognizes Clinical Ink as High-Growth Startup Poised for Significant Growth Based on Record of Disrupting Life Sciences With Innovative Technology
...
HALIFAX, NOVA SCOTIA: All Animals Receiving a Single Dose of DepoVax(TM) Formulated Anthrax Vaccine Survive; Significant Immune Response Detected as Early as 14 Days Following Vaccination
...
LONDON, ONTARIO: Initial results suggest that COTI-2 has potential for another unmet cancer need
...
HUDSON, NY: Excluded Flora Standard Allows for Models Free of Two Additional Commensal Organisms
...
TACOMA, WA: Multiple Published Research Studies Outline the Potential for RNS60 to Effectively Treat Alzheimer's Disease by Protecting Neuronal Function and Restoring Neuronal Plasticity
...
TACOMA, WA: Adds Proven Industry Leadership to Accelerate RNS60 Commercialization
...
LONDON, ONTARIO: Increases Runway Into the Clinic for Lead Cancer Drug Candidate COTI-2
...
